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a b s t r a c t
Objectives: To estimate the percentage of adherence to highly-active antiretroviral therapy (HAART) in
Spanish observational studies and to identify the variables associated with adherence.
Methods: Seven electronic databases were used to locate the studies. Six inclusion criteria were estab-
lished. Two coders codiﬁed the variables independently. Intercoder reliabilitywas calculated. Publication
bias was analyzed through the Begg, Egger and Trim and Fill tests. Homogeneity was evaluated using the
Q test and the l2 index. A random effects model was assumed to estimate both the overall percentage of
adherence and to explain heterogeneity.
Results: This meta-analysis included 23 observational studies, yielding a total of 34 adherence estimates.
The sample was composed of 9,931 HIV-positive individuals (72% men) older than 18 years under treat-
mentwithHAART.Thepercentageofpatients adhering toan intakeof>90%of theprescribedantiretroviral
drugs was 55%. Wide heterogeneity was detected (I2 = 91.20; 95%CI: 88.75-93.13). Adherence was mainly
measured using a single strategy (47.8%), themostwidely used being self-report (48.7%). In the univariate
analysis, the following factors were signiﬁcant: infection stages A (=0.68, p <0.001) and B (=–0.56,
p <0.01), viral loads >200 copies/ml (=–0.41, p <0.05) and <200 (=0.39, p <0.05), and university
education (=–0.66, p<0.05).
Conclusions: The overall percentage of adherence was 55%, although this value may be an overestimate.
Adherence was associated with infection stage A and with a viral load of <200 copies/ml.
© 2010 SESPAS. Published by Elsevier España, S.L. All rights reserved.
Adherencia al tratamiento antirretroviral de gran actividad (TARGA) en Espan˜a.
Un metaanálisis
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r e s u m e n
Objetivo: Calcular el porcentaje de adherencia al TARGA en estudios observacionales espan˜oles, así como
identiﬁcar las variables asociadas a ella.
Métodos: Para localizar los estudios se emplearon siete bases bibliográﬁcas. Se establecieron seis criterios
de inclusión. Dos codiﬁcadores realizaron la codiﬁcación de forma independiente. Se calculó la ﬁabilidad
intercodiﬁcadores. El sesgo de publicación se evaluó mediante los tests de Begg y de Egger, y Trim & Fill.
La homogeneidad se estimómediante la pruebaQy el índice I2. Se asumió unmodelo de efectos aleatorios
tanto para la estimación del porcentaje global de adherencia como para explicar la heterogeneidad.
Resultados: El metaanálisis incluyó 23 estudios observacionales que proporcionaron 34 estimaciones de
la adherencia. Lamuestra está constituida por 9931 individuosVIH+ (72,2%hombres),mayores de 18 an˜os
y en tratamiento con TARGA. El porcentaje de pacientes con una adherencia al tratamiento de >90% de
ingestión de los antirretrovirales prescritos fue del 55%. Se detectó una gran heterogeneidad (I2 = 91.20;
IC95%: 88.75-93.13). La adherencia fue evaluada principalmente con una única estrategia (47,8%); el
autoinforme fue la más empleada (48,7%). En el análisis univariado resultaron signiﬁcativo los estadios
A (=0,68, p <0,001) y B (= -0,56, p <0,01), la carga viral >200 copias/ml (= -0,41, p <0,05) y <200
copias/ml (=0,39, p <0,05), y el nivel de educación de estudios superiores (= -0,66, p <0,05).
Conclusiones: El porcentaje global de adherencia fue del 55%, pero este valor puede estar sobrestimado.
La adherencia se asoció al estadio A de la infección y a una carga viral <200 copias/ml.
010 S© 2
ntroductionHighly active antiretroviral therapy (HAART) has improved the
linical status and prognosis of most patients infected with HIV,
∗ Corresponding author.
E-mail address: ortegoc@unican.es (C. Ortego).
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decreasing their morbidity and mortality1–3. Therefore, since 1997
and coinciding with the widespread use of HAART, opportunistic
infections have markedly decreased and the quality of life of HIV-
infected patients has improved4.Studies of the ﬁrst HAART claimed that almost perfect adher-
ence, classically greater than 95%5,6, was required to obtain
maximal effectiveness. Recent studies have suggested that ther-
apeutic objectives can be attained at lower levels of compliance
ts reserved.
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Table 1
Description of the studies included in the meta-analysis.
Authors Year Data base Design Duration
(weeks)
Cut-off Number of
strategies
n
baseline
Type of
group
Proportion of adherence
Baseline Between
4-16 weeks
Between
17-26 weeks
More than
27 weeks
Abellán J et al 1999 No L 16 >90% 1 78 A 0.82
86 B 0.70
Alcoba M et al 2003 No C >90% 3 106 0.58
Codina C et al 2002 No L 52 >90% 3 96 0.83
Escobar I 2003 No L 52 >95% 2 88 0.52 0.47 0.24
Fumaz CR et al 2008 No C >95 2 87 0.62
García de Olalla P et al 2002 Yes (table) C >90% 2 385 Men 0.62
173 Women 0.58
Gordillo V et al 1999 No C >90% 2 366 0.58
Inés SM et al 2008 No C >90 1 50 0.42
Knobel H et al. 2002 Yesa L 52 >90% 3 3004 0.63 0.65 0.68
Knobel H et al 2004 Yesa L 48 >90% 1 85 0.49
Ladero L et al 2005 Yes L 52 >95% 1 80 Men 0.45 0.41
20 Women 0.35 0.45
Martín MT et al 2007 Yes L 26 >90% 1 1427 Men 0.69
509 Women 0.59
Martín J et al 2001 Yes C >90% 2 155 Men 0.39
59 Women 0.31
Martín V et al 2002 No C >90% 2 206 0.48
Morillo R et al 2005 Yes (table) L 12 >95% 1 85 Men 0.56
29 Women 0.55
Ortega L et al 2004 No C >90% 3 136 0.44
Remor E 2000 Yes (table) L 26 >90% 1 59 Men 0.14
41 Women 0.15
Riera M et al 2002 Yes L 39 >90% 2 147 Men 0.66
55 Women 0.39
Ruiz I et al 2006 No C >90% 1 320 0.88
Tornero C et al 2005 Yes C >90% 1 68 Men 0.74
39 Women 0.72
Ventura JM et al 2006 Yes C >95% 2 46 Men 0.37
19 Women 0.37
Ventura JM et al 2007 No C >90% 1 234 0.47
Viciana P et al 2008 No L 26 >90% 1 611 QD 0.61
367 BID 0.53
C: cross-sectional; L: longitudinal; A: conventional medical assessment; B: protocolized assessment; QD: once-daily dosing; BID: twice-daily dosing.
a Could not be used.
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Table 2
Description of the sample.
Variables Levels n % k
Sex
Man 6740 72.23 34
Woman 2591 27.77 34
Age M (SD) 37.87 (0.826) 34
Educational level None 295 9.85 10
Primary 415 13.86 9
Secondary 2139 71.44 11
High 145 4.84 6
Employment status Not working 500 38.88 9
Active 786 61.12 10
Living Alone 42 13.95 4
With other(s) 259 86.05 4
Group Heterosexual 2334 27.52 27
Homosexual 1726 20.35 22
IVDU 4420 52.12 27
Route of infection Sexual 3596 46.3 25
Parenteral 4072 52.43 25
Both 99 1.27 4
E stage baseline A 1431 35.57 15
B 1182 29.38 15
C 1410 35.05 15
AIDS 1588 39.47 17
Baseline viral load >200 copies/ml 765 43.86 20
<200 copies/ml 979 56.14 19
End viral load >200 copies/ml 619 31.18 10
<200 copies/ml 1366 68.82 11
Baseline CD4 >200 cells/ml 1524 73.38 19
<200 cells/ml 553 26.62 19
End CD4 >200 cells/ml 2061 86.13 11
<200 cells/ml 332 13.87 11
Active IVDU 91 6
In methadone program 307 12
Psychiatric comorbidity 300 4
Adverse reactions 820 9
Naïve 974 1684 C. Ortego et al / Gac S
n regimens based on non-nucleoside analog reverse-transcriptase
nd protease inhibitors boosted with ritonavir, especially in
atients who achieved undetectable viremias7–10.
Although viral suppression is feasible with moderate levels of
dherence to HAART, several studies have shown that the emer-
ence of resistant strains11,12 and mortality13 increase with lower
dherence.
Althoughmany studies have evaluated adherence toHAART and
ts associated variables, their results vary depending onhowadher-
nce was measured, the characteristics of the samples, and the
emaining variables analyzed. A systematic review identifying and
xplaining these discrepancies is required to increase adherence to
AART.
In Spain, the prevalence of HIV is around three infections
er thousand inhabitants14. Although the incidence of AIDS has
arkedly decreased since the new antiretroviral treatments began
o be used, Spain remains one of the countries with the highest
ncidence of AIDS inWestern Europe15,16. In this country, antiretro-
iralmedicines are administered freeof charge through themedical
harmacological services of the public health system. The over-
ll annual expenditure on these medicines has been estimated
o be more than a seventh of the total medical pharmacological
xpenditure17,18.
No meta-analyses of adherence to HAART in the Spanish pop-
lation have been published. The number of studies on adherence
o HAART in Spain has increased, allowing them to be systemati-
ally reviewed and to shed light on the design and improvement of
tudies of HAART adherence interventions.
The objective of this study was to carry out a meta-analysis of
AART adherence in Spain and to synthesize observational studies
n order to estimate average adherence and identify the variables
ssociated with this adherence.
ethods
earch strategy and study selection
The studies were selected from (a) seven electronic databases
PsycInfo, Medline, IME, EMI, Teseo, IBECS, ISOC and ISI Web of
nowledge) using a boolean search on the title of any type of
ublication: {[HAART OR highly active antiretroviral therapy] AND
dheren* AND [HIV OR AIDS OR (human immu* virus) OR (acquired
mmu* syndrome)] AND [Spanish OR Spain]}; (b) Web browsers;
c) the summary of the latest conference proceedings; (d) funded
rojects on HIV / AIDS in Spain and (e) tracing of references cited
n others studies. The studies had to be written either in English or
n Spanish.
Studieswere included in the review if they (a) aimed to evaluate
dherence to HAART in a Spanish sample, (b) had a cross-sectional
r cohort design, (c)evaluatedanHIV-positive sampleover18years
ld under treatment with HAART, (d) measured adherence at least
nce and using one strategy, (e) established an intake of >90% or
5% of themedication prescribed as the cut-off point for adherence,
nd (f) provided sufﬁcient information to obtain the proportion of
dherence to HAART.
The search ended on September 13, 2009 and studies from 1998
ere included. Twenty-three independent studies that met the
ix selection criteria were included in this meta-analysis (table 1).
hese 23 primary studies19–41 provided 34 estimates of adherence
o HAART. In three studies20,32,34 the total independence among
heir samples could not be checked.The authors of 21 of the 23 primary studies included in
he meta-analysis were emailed to request information on the
atabases they had used in their studies or at least a set of
ata that would allow two groups to be constructed: men andn: number of subjects; k: number of studies; %: percentage of individuals; IVDU:
intravenous drug user.
women.Nineteenauthors responded to themessage. Thedatabases
of eight studies and additional data from three studies were
received.
Coding
Two independent trained raters coded each study follow-
ing the coding manual (available from the main author on
request). The ﬁnal coding form registered 42 variables, which
were grouped into three sets: “extrinsic”, of the “design” and the
“sample”.
Althoughnoscale toassess themethodological qualitywasused,
a small group of variables related to the methodological design
were coded to compare adherence according to the studies’ char-
acteristics.
Calculation of effect sizes and study outcomes
The proportion of adherence to HAART was estimated in each
study as the effect size index. When, due to gender or location,
more than one group could be drawn from a study, separate esti-
mates of adherence were calculated for each group. If adherence
was measured with more than one strategy, the average adher-
ence was calculated. If the study evaluated adherence at different
time points, the ﬁrst assessment of adherence was chosen to avoid
dependence, although a sensitivity analysis was performed for
each set of measurements including all the possible comparisons.
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ecause the length of follow-up varied widely across studies, we
ivided outcomes into four measurement intervals as a strategy
o examine all study assessments: between 0-3 weeks (k =21),
etween 4-16 weeks (k =3), between 17-26 weeks (k =6), more
han 27 weeks (k =4).
To ensure the normality of the effect size index, all the statistics
ere obtained using a logit transformation of the proportion of
dherence (T = ln
(
p
1−p
)
),wherepwas theproportionof adherence
or each comparison. Then, themeta-analysis using a randomeffect
odel weighted by the inverse variance was performed. Finally,
ll the results were transformed back to a proportion for a more
omprehensive interpretation of the data using the formula42 p =
eT
1+eT . This outcome ranges from 0 to 1, where 1 indicates that all
he patients have achieved high adherence (at least >90%), while 0
ndicates that no patient has exceeded this cut-off point.
Homogeneity was evaluated using the Q test and the I2 index
ith its conﬁdence interval43. The relationship among study
imensions and the proportion of adherence variability was exam-
ned by using modiﬁed least squares regression analyses with
eights equivalent to the inverse of the variance for each effect
ize. When feasible factors related signiﬁcantly to the propor-
ion of adherence, they were entered into a series of modelsst plot.
controlling for intercorrelations among the maintained study
dimensions. These combined models allowed determination of
the extent to which variation might be exclusively attributed to
surviving study dimensions or not. The continuous variables that
were signiﬁcant in the univariate analyses were zero-centered
to reduce multicollinearity44; if they were categorical, dummy
variables were created44. Models with simultaneous indepen-
dent variables were created if these factors were registered in
more than ﬁve studies (k >5) and under mixed-effects assump-
tions, which are considered to have more conservative statistical
power45.
The publication bias was analyzed through three different
strategies: Trim and Fill46, Begg’s strategy47, and the Egger
test48.
Results
Study and adherence characteristics, and sampleThe characteristics of the 23 primary studieswere as follows: 21
(91.3%) studies were published and two (8.7%) were unpublished
(doctoral theses), 10 (43.5%)werewritten in English and 13 (56.5%)
2 anit. 2011;25(4):282–289
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Table 3
Univariate analysis. Mixed effects model.
Variables Proportion of
adherence
IC95% ˇ
Study design
Design -0.023
Longitudinal (k=18) 0.56 0.5-0.62
Cross-sectional (k=16) 0.55 0.49-0.61
Screening interval (weeks) 0.05
Between 0 - 3 (k=21) 0.54 0.6-0.76
Between 4 – 16 (k=3) 0.72 0.83-0.94
Between 17 - 26 (k=6) 0.47 0.59-0.38
More than 27 (k=4) 0.61 0.74-0.82
Cut-off for adherence 0.26
>95% (k =8) 0.49 0.39-0.58
>90% (k =26) 0.57 0.52-0.62
N◦ of strategies (k = 34) 0.01
One (k=18) 0.57 0.63-0.89
Two (k =12) 0.5 0.58-0.5
Three (k =4) 0.63 0.74-0.87
Sample characteristics
% Men (k =34) 0.18
0 0.49 0.41-0.58
100 0.59 0.53-0.65
% Women (k =34) -0.18
0 0.59 0.53-0.65
100 0.49 0.4-0.58
Mean year (k = 34) 0.2
32 0.48 0.38-0.58
44 0.64 0.53-0.73
% High educational level (k = 6) -0.66a
9 0.68 0.4-0.87
37 0.16 0.04-0.48
% Working (k = 10) 0.48
34 0.36 0.17-0.62
64,37 0.65 0.5-0.78
% Currently active IVDU (k =6) 0.13
27 0.63 0.54-0.72
78 0.56 0.47-0.65
% Methadone (k =12) -0.52
2 0.53 0.32-0.73
18 0.59 0.32-0.82
% Stage A (k =15) 0.68b
15 0.29 0.21-0.38
55 0.79 0.66-0.88
% Stage B (k =15) -0.56c
8 0.72 0.55-0.84
46 0.33 0.24-0.44
% Baseline viral load > 200 copies/ml
(k = 20)
-0.41a
10 0.59 0.47-0.7
100 0.3 0.17-0.48
% Baseline viral load < 200 copies/ml
(k = 19)
0.39a
0 0.3 0.16-0.5
80 0.59 0.46-0.72
% Adverse reactions (k = 9) 0.21
14 0.54 0.41-0.66
45 0.6 0.5-0.72
IVDU= intravenous drug user.
a p<0.05.
b p<0.001.
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n Spanish, 12 (52.2%) had a cross-sectional design and 11 (47.8%)
longitudinal design. All of the studies were performed between
998 and 2008.
Patients with an intake of >90% of prescribed HAART were con-
idered adherent. Adherence was assessed using just one strategy
n 11 studies (47.8%), two strategies in eight (34.8%) and three
trategies in four (17.4%). Self-report was the most frequently used
trategy to quantify adherence in 19 studies (48.7%), followed by
egistration of dispensing medicines in 11 (28.2%), plasma drug
oncentration in four (10.3%), counting of surplus medication in
wo (5.1%), viral load in two (5.1%) and electronic devices in one
2.6%).
From the 23 studies included in table 1, a sample (table 2) com-
osed of 9,331 HIV-positive patients older than 18 years under
AART was obtained, with 6,740 (72.2%) men and 2,591 (27.8%)
omen and a mean age of 37.9 years (SD: 2.83, range: 33-44).
verall adherence to HAART
The average adherence to HAART under the random effects
odel for the Spanish sample was 0.54 (95%CI: 0.49-0.59), show-
ng wide heterogeneity (I2 = 91.20; 95%CI: 88.75-93.13) under the
xed-effects model. Therefore, only the results under the random-
ffectsmodel andmixed-effectsmodel toexplain theheterogeneity
ot explained by the model (I2 = 51%; 95%CI: 11.45-72.88) are pre-
ented. Chart 1 shows the forest plot of the proportion of adherence
f the 34 groups as well as the overall mean proportion of adher-
nce (at the bottom of the chart). Chart 2 shows the proportion of
dherence by sex.
A sensitivity analysis was performed to (i) test the inﬂuence of
ossible outliers, (ii) test thepatterns of the set of studies dividedby
he week of measurement, and (iii) determine whether the results
ere affected by the exclusion of some studies in which the total
ndependence among their samples could not be checked. Compar-
son of all the possible outliers revealed that none worked as a real
utlier. The time interval showed the same patterns when the data
ere analyzed by interval as a separate meta-analysis rather than
s a moderator without inclusion of more than one measurement
er study. Finally, we decided to maintain all studies with a likely
ependence because their exclusion did not affect the ﬁnal results
ut would involve a substantial loss of information.
Intercoder reliability was higher than 0.90. Cohen’s kappa was
sed for categorical variables (=0.98) and the Spearman-Brown
orrelation coefﬁcient for continuous variables (r = 0.955). Dis-
greements were solved through discussion.
The three tests used to assess possible publication bias aimed to
how absence of bias. These testswere the Trim and Fill (the results
ndicate that there are no missing studies), Begg’s test (z =–0.10,
= 0.922) and Egger’s test (bias = -1.58, t = –1.98, p =0.054).
actors modifying adherence to HAART
A higher percentage of participants in stage A and with base-
ine viral load <200 copies/ml showed greater adherence. However,
ower adherence was found when a higher percentage of patients
ere in stage B, with a baseline viral load >200 copies/ml, and with
high level of education, that is, education from secondary school
nwards (table 3; this table depicts the variables registered inmore
han ﬁve groups, k >5).
Some of the signiﬁcant moderators showed high collinearity
rs > 0.90, e.g., stage A and stage B, the two variables for base-
ine viral load) and therefore separate combined models were
ested by different groups of moderators, avoiding dependence
mong them and excluding high educational level due to the
mall number of studies reporting this data (k =6). After all the
ossible combinations of stage and baseline viral load, the onlyp<0.01.
For categorical variables with more than one category, the value is not  but the R
multiple of the regression model.
variable that remained signiﬁcant when baseline viral load (> 200
copies/ml because this value was measured in the largest number
of studies) was controlled for was the percentage of patients in
stage A. The model explaining 52% of the variance, more than
expected by chance, was stage A (=0.69, p =0.0005) controlling
by baseline viral load > 200 copies /ml (=–0.21, p =0.30), yielding
the following regression equation (expressed in the unstandard-
ized coefﬁcients, the B values): –1.637+0.060 x (stage A) –0.0078
(baseline viral load > 200 copies/ml).
C. Ortego et al / Gac Sanit. 2011;25(4):282–289 287
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iscussion
The main result of this study is that adherence to HAART in
pain is 55%. This percentage is similar or slightly lower than that
ound by other authors in individuals from different populations
orldwide49–55. However, in this meta-analysis, this value could
e overestimated for two reasons: ﬁrstly, adherence was assessed
y a single strategy in more than half of the primary studies and
econdly, because the most widely used strategy was self-report.
When the variable of baseline viral load < 200 copies/ml was
ontrolled for, the higher the percentage of patients in stage A,
he greater the adherence. Other studies have also found lower
dherence in patients with high viral loads than in those with low
oads56,57. The stage of infection was closely related to the viral
oad, indicating the importanceof controlling for this variable in the
nalmodel. In thismeta-analysis, the higher percentage of subjects
n stage A, the greater the adherence, whereas the higher per-
entage of subjects in stage B, the lower the adherence. Similarly,
everal authors found greater adherence in patients with a shorter
ime since infection58–60. Quality of life61, degree of distress62 and
atients’ expectations of treatment could be determining variables
n these results.
Although the level of education was signiﬁcant, this variable
as only registered in six studies. Thus, more research is needed to
nable generalizations related to this moderator to be made.st plot.
This meta-analysis also codiﬁed other variables that several
studies have found to be associated with higher adherence:
male gender63–67, older age68–72, having a stable job58,59,73,
not having adverse reactions50,63,66,73–76, not consuming illegal
drugs53,65,66,76–79, not drinking alcohol53,65,74,79, not having psy-
chiatric comorbidity49,50,53,77,78,80 and having some support49,58,78.
Although all these variables were signiﬁcant in the univariate level
and under a ﬁxed effectsmodel, they lost their signiﬁcance in order
to assume a random effects model.
One of the limitations of this study is the small number of vari-
ables registered in the primary studies. Spanish studies assessing
adherence to HAART are generally highly restrictive in the num-
ber of variables analyzed, often limited to recording the most
common demographic, biological or pharmacological variables,
without recording those that seem to play a role of equal or greater
weight in the adherence to HAART, such as psychosocial variables.
Although this meta-analysis codiﬁed 42 variables, most could not
be used in the multivariate analysis given the small percentage
of studies that recorded them, which signiﬁcantly restricted the
analysis of heterogeneity.
Another limitation is the wide heterogeneity of this meta-
analysis. The small number of studies identiﬁed to form part of
this meta-analysis also played a decisive role in these limitations.
Adherence to the HAART in Spanish samples should continue
to be assessed in order to determine variability and improve
2 anit. 2
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dherence. However, adherence should be measured by more
han one strategy to avoid its overestimation and follow experts
ecommendations81. Assessments of adherence should record a
arger number of variables because, although many of the variables
odiﬁed in this meta-analysis were signiﬁcant, the small number
f studies that recorded them prevented this model from being
mployed as an explanatory model. Finally, stage A and viral base-
ine load < 200 copies/ml were signiﬁcantly associated with higher
dherence, whereas stage B and viral baseline load > 200 copies/ml
ere associated with lower adherence. Therefore, programs aimed
t maintaining and increasing adherence should be aware of both
atients’ stage of infection and their viral baseline load.
Adherence to HAART should be approached from multidisci-
linary, multifactorial and biopsychosocial per spectives. Greater
ollaboration among researcherswould help to gain further knowl-
dge and reduce duplication of efforts82.
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